Uncovering the role of Gpr45 in obesity regulation
Gpr45 is a putative therapeutic candidate that could be targeted to combat obesity and overeating.
Authors
- Monica M. Li
- Ryan M. Esquejo (ORCID: https://orcid.org/0009-0003-3996-8318)
- Eva O. Karolczak
- Cuiying Xiao (ORCID: https://orcid.org/0000-0002-9370-1230)
- Chia Li
- Claire Gao (ORCID: https://orcid.org/0000-0002-8832-5103)
- Michael J. Krashes (ORCID: https://orcid.org/0000-0003-0966-3401)
- Marc L. Reitman (ORCID: https://orcid.org/0000-0002-0426-9475)
- Ivan C. Alcantara (ORCID: https://orcid.org/0000-0002-0987-2118)
- Kendra K. Bence (ORCID: https://orcid.org/0000-0002-5879-4726)
- Junjie Li (ORCID: https://orcid.org/0000-0003-4542-300X)
- Jean‐Philippe Fortin
- Isabel M Cohen
- Abigail I Goldschmidt
- Cynthia A Pinkus
Institutions
- National Institutes of Health (US)
- Pfizer (United States) (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
Publication Details
- Journal
- Molecular Metabolism
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1016/j.molmet.2025.102174
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute of Diabetes and Digestive and Kidney Diseases